Levetiracetam + Carbamazepine + Lamotrigine

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Focal Epilepsy

Conditions

Focal Epilepsy

Trial Timeline

Jan 1, 2007 → Aug 1, 2011

About Levetiracetam + Carbamazepine + Lamotrigine

Levetiracetam + Carbamazepine + Lamotrigine is a approved stage product being developed by UCB for Focal Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT00438451. Target conditions include Focal Epilepsy.

What happened to similar drugs?

3 of 9 similar drugs in Focal Epilepsy were approved

Approved (3) Terminated (1) Active (6)

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00438451ApprovedCompleted

Competing Products

20 competing products in Focal Epilepsy

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
35
DapagliflozinAstraZenecaApproved
43
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
35
CCX140-BAmgenPhase 2
27
PF-06730512PfizerPhase 2
27
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
43
VX-147Vertex PharmaceuticalsPhase 2
35
VX-147Vertex PharmaceuticalsPhase 1
29
IXPVertex PharmaceuticalsPhase 1
29
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
35
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
29
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
42
VivaglobinCSLPhase 2
35
UCB0942UCBPhase 2
27
Brivaracetam + BrivaracetamUCBPhase 2
35
LacosamideUCBPhase 2
27
UCB0942 + UCB0942 + PlaceboUCBPhase 2
35
LacosamideUCBPre-clinical
26
ARGX-117ArgenxPhase 2
36
Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
44